Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

COVID-19

Enhancing antibodies

Cell https://doi.org/10.1016/j.cell.2021.05.032 (2021)

Antibodies against viruses are not always protective. In Cell, Arase and colleagues identify Abs against SARS-CoV-2 that bind the N-terminal domain (NTD) of the spike (S) protein and induce an open conformation of the receptor-binding domain (RBD), which results in enhanced binding to the virus receptor ACE2 and enhanced infectivity. In a screen of Abs isolated from patients with COVID-19, some of the Abs to NTD enhance the binding of S protein to ACE2 to a level higher than that of the D614G mutant S protein, which is known to have an open RBD conformation. All enhancing Abs bind the same sites (W64, H66, V213 and R214) in the S protein, dock similarly on the NTD and induce the open RBD state. Enhancing Abs reduce the neutralizing capacity of neutralizing Abs. Patients with COVID-19 have both enhancing and neutralizing Abs, and the difference between enhancing and neutralizing titers is greater in patients with severe as compared to non-severe disease.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ioana Visan.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Visan, I. Enhancing antibodies. Nat Immunol 22, 800 (2021). https://doi.org/10.1038/s41590-021-00973-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-021-00973-7

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing